Does HRT help long-term bone health?

For many postmenopausal women, HRT can help protect long-term bone health. Whether it is the most appropriate option depends on individual health factors that a prescriber should evaluate.

How HRT Supports Bone Strength

According to current NAMS guidelines, estrogen plays a key role in maintaining bone remodeling balance. After menopause, estrogen levels decline sharply, and per published clinical guidelines, this accelerates bone resorption relative to bone formation. HRT replaces a steady amount of estrogen, which, per the Endocrine Society, helps slow bone breakdown and supports maintenance of bone density.

What the Research Shows

• Stronger bone density: According to the WHI long-term follow-up data, women on HRT consistently showed higher bone mineral density in the spine and hips compared with women not using HRT.
• Lower fracture risk: Per the WHI long-term follow-up data, fewer hip, spine, and wrist fractures were observed in women taking HRT, particularly when treatment was initiated near the onset of menopause.
• Duration of protection: According to current NAMS guidelines, bone benefits persist during treatment and decline gradually after stopping, consistent with the mechanism of hormonal support.

Who May Benefit

• Women in early menopause: Per published clinical guidelines, initiating HRT within approximately 10 years of the last menstrual period is associated with more predictable bone protection outcomes.
• Women with early or accelerated bone loss: According to ACOG, HRT may help prevent progression from osteopenia to osteoporosis in women with documented early bone density decline.

Types of Hormone Therapy

Per FDA-approved prescribing information, transdermal estrogen (patch, gel, spray) and oral estrogen are established forms of HRT studied for bone protection. Women with a uterus also require progesterone to protect the uterine lining, and per published clinical guidelines, this does not diminish bone-related benefits. Both FDA-approved products and compounded preparations may be used to deliver estrogen; however, the evidence base for bone outcomes is derived primarily from studies of FDA-approved formulations.

Compounded medications are not FDA-approved. They have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved medications should be considered first when commercially available options meet patient needs.

Summary

According to current NAMS guidelines, HRT is among the most studied interventions for postmenopausal bone loss and fracture prevention, acting through estrogen-dependent mechanisms that support bone density over time. Per published clinical guidelines, long-term benefit is associated with consistent treatment and appropriate patient selection.

Whether HRT is appropriate depends on individual health factors. A prescriber should determine the best approach based on a patient's complete medical history.